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Abstract
Eculizumab was used to treat an 86-year-old male patient with paroxysmal nocturnal hemoglobinuria, the oldest
reported case in Japan. As observed in younger patients, this drug rapidly suppressed hemolysis in the present
patient, which allowed weaning from blood transfusion. Eculizumab treatment has been continued for 2 years and
resulted in the alleviation of renal dysfunction. Despite the patient’s advanced age, the inhibition of complement
activity caused by this drug did not result in infection, indicating that it is safe to use in elderly patients.
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Background
The complement regulatory proteins CD55 and CD59
bind to glycosylphosphatidylinositol (GPI) on red blood
cell membranes and inhibit complement activity, thus pre-
venting hemolysis. Paroxysmal nocturnal hemoglobinuria
(PNH) is a disease that involves hemolysis caused by the
lack of CD55- or CD59-mediated complement activity in-
hibition in the absence of GPI anchor on the surface of red
blood cells. This occurs in individuals with a defective
phosphatidylinositol glycan class A enzyme that prevents
normal GPI anchor synthesis (Takahashi et al. 1993). PNH
is a very rare disease that develops in approximately 16 per
1 million people, and its onset does not exhibit any age
specificity (Hillmen et al. 1995; Nishimura et al. 2004).
Hemoglobin release into the bloodstream as a result of
hemolysis could lead to massive nitrogen oxide (NO) scav-
enging in blood vessels; this increases platelet reactivity
and aggregation, possibly inducing pulmonary hyperten-
sion and/or thrombosis. Hemolysis can also lead to several
disorders including renal dysfunction due to massive
hemosiderin deposition in the proximal renal tubules.
The immune systems of elderly patients are generally com-
promised compared with those of younger patients (Naylor
et al. 2005; Czesnikiewicz-Guzik et al. 2008). However,
whether elderly patients with PNH can be safely treated
using medicines that inhibit complement activity remains
unknown.
We recently encountered a rare case of PNH diag-
nosed at the age of 81 years, in which eculizumab treat-
ment was initiated at the age of 84 years. The details of
the clinical course of this patient are presented herein.
Case description
A 84-year-old man was diagnosed with anemia at a local
facility in March 2009 and referred to a specialist. Upon
examination at the facility, the patient was conscious,
and his palpebral conjunctiva exhibited signs of anemia
but no yellowing. His skin showed signs of anemia, but
no purpura was detected. No superficial lymph nodes
were palpable. No swelling of the liver or spleen, or
significant heart or lung disorder was observed. The
hematological test results were as follows: red blood cell
(RBC) count, 241 × 104/μL; hemoglobin (Hb), 8.4 g/dL;
hematocrit, 26%; reticulocytes, 3.1%; and white blood
cell (WBC) count, 3,370/μL (48.3% neutrophils, 41.2%
lymphocytes, and 3.8% eosinophils). The biochemical
test results were as follows: lactate dehydrogenase
(LDH), 1,073 U/L; aspartate aminotransferase (AST),
54 U/L; serum creatinine (sCr), 1.49 mg/dL; blood urea
nitrogen, 15 mg/dL; vitamin B12, >1,500 pg/mL; hapto-
globin, <10 mg/dL; and direct Coombs test result, negative
(Table 1).
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Bone marrow aspiration in April 2009 demonstrated
hypercellular marrow: nuclear cell count (NCC), 21.3 ×
104/mm3; megakaryocytes (MgK), 53/mm3 with bilineage
dysplasia (i.e., peroxidase-negative myeloid cells, mono-
nuclear megakaryocytes, and increased total erythroblasts
[58.8%]). Chromosome analysis revealed a karyotype of
45X-Y(4)/46XY(16). Therefore, the patient was diag-
nosed with myelodysplastic syndrome (MDS), i.e., re-
fractory cytopenia with multilineage dysplasia. His anemia
gradually progressed, and he occasionally required blood
transfusion.
In November 2010, the patient’s urine output exhibited
a cola color. Flow cytometric analysis of red blood cells
at the time revealed 1.31% CD55(−) cells and 49.1%
CD59(−) cells, prompting a diagnosis of PNH (Figure 1).
In January 2011, infectious enteritis triggered hemolysis,
which warranted blood transfusion. Oral treatment with
methenolone 15 mg/day and prednisolone 10 mg/day
was subsequently initiated, alleviating the patient’s de-
pendence on blood transfusion. However, his hemolysis
continued, and renal function gradually deteriorated;
estimated glomerular filtration rate (eGFR) decreased
from 35.9 mL⋅min−1⋅1.73 m−2 at the patient’s first visit
to 25.2 mL⋅min−1⋅1.73 m−2. Therefore, eculizumab treat-
ment was initiated in November 2011. Meningococcus
vaccine was administered 2 weeks before eculizumab
intervention.
Hematological tests performed immediately before
eculizumab treatment initiation yielded the following re-
sults: RBC, 280 × 104/μL; Hb, 10.0 g/dL; and reticulo-
cytes, 4.1%. The biochemical test results were as follows:
LDH, 1,748 U/L; and total bilirubin, 2.4 mg/dL.
Eculizumab treatment rapidly reduced LDH levels,
which returned to normal (i.e., 234 U/L) 4 weeks after
treatment initiation and remained normal thereafter
(Figure 2). In February 2012, the percentages of CD55(−)
and CD59(−) cells increased to 53.97% and 47.31%, re-
spectively (Figure 1). Ten months after eculizumab admin-
istration, the patient suddenly developed symptoms of
anemia, which necessitated blood transfusion. However,
this episode was not caused by PNH-induced hemolysis
but rather by a bleeding ulcer from the remaining part of
the stomach after previous gastric cancer surgery. The
ulcer healed in response to fasting and treatment with a
proton pump inhibitor and did not trigger a hemolytic
attack. No infection-associated adverse events occurred.
Blood transfusion was no longer required thereafter. The
patient experienced persistent suppression of hemolysis
Table 1 Laboratory findings on diagnosis (March 6, 2009)
Hematology Biochemistry
RBC 241 × 104/μL T-Bil 1.0 mg/dL
Hb 8.4 g/dL AST 54 U/L
Ht 26% ALT 16 U/L
MCV 107.9 Fl LDH 1,073 U/L
MCH 34.9 pg ALP 221 U/L
MCHC 32.3 g/dL BUN 15 mg/dL
PLT 12.6 × 104/μL CRE 1.49 mg/dL
Reticulocyte 3.1% CRP <0.1 mg/dL
WBC 3,370/μL Fe 76 μg/dL







Figure 1 Flow cytometry of red blood cells. A-1: CD55
(pre-eculizumab). A-2: CD59 (pre-eculizumab). B: CD55/CD59
(post-eculizumab).
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and renal function recovery, with sCr levels decreasing
from 2.0 mg/dL (eGFR, 25.4 mL⋅min−1⋅1.73 m−2) to
1.4 mg/dL (eGFR, 37.5 mL⋅min−1⋅1.73 m−2).
Discussion and evaluation
Patients with PNH associated with hemolysis are known
to present with symptoms including abdominal pain,
dysphagia, and pulmonary hypertension due to excessive
NO scavenging by hemoglobin released into the blood
or thrombosis at various sites as a result of stimulated
platelet aggregation (Hill et al. 2010; Rother et al. 2005).
Anemia secondary to hemolysis used to be treated with
blood transfusion, steroids, or the anticoagulant warfarin
(Parker et al. 2005; Hillmen et al. 2007). However, the
use of eculizumab, which specifically inhibits comple-
ment C5, was approved in Japan in 2010. The comple-
ment regulatory proteins CD55 and CD59 play roles in
hemolysis prevention. While CD55 regulates the first
half of the complement activation pathway by stimulat-
ing the destruction of the C3/C5 converting enzyme,
CD59 acts on C9 and inhibits the formation of the
membrane attack complex (Nicholson-Weller et al. 1981;
Sugita et al. 1988; Davies et al. 1989). When the present
patient was diagnosed with PNH, the percentages of
CD55(−) and CD59(−) cells were 1.31% and 49.1%, re-
spectively. The sensitivity of the complement system
increases particularly when CD59 is defective; this can
lead to the hemolysis of PNH-affected blood cells. There-
fore, this mechanism likely led to PNH development in
the present case despite the lower percentage of CD55-
negative cells detected. Eculizumab reduces LDH levels
soon after treatment initiation (Hillmen et al. 2007). Fur-
thermore, as hemolysis is alleviated by this drug, Hb
levels gradually increase (Hillmen et al. 2007; Kanakura
et al. 2011). The present patient was initially diagnosed
with MDS and exhibited increased WBC counts in re-
sponse to treatment with methenolone and prednisol-
one. However, because compromised renal function
was still observed, the possibility of PNH-induced chronic
renal failure and a subsequent poor prognosis was consid-
ered. Therefore, treatment with eculizumab was initiated.
Compromised renal function is relatively frequent in
Figure 2 Clinical changes observed in the patient.
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patients with PNH. In the AEGIS Study, an indication
study in Japan, as much as 66% of the patients studied
were associated with abnormal renal function. Another
study reports that 18% of Japanese patients with PNH
died from renal failure (Nishimura et al. 2004). Further-
more, Japanese and global studies demonstrate improved
renal function in 30–40% of all patients receiving pro-
longed eculizumab treatment (Kanakura et al. 2011;
Hillmen et al. 2010). Therefore, eculizumab treatment
could be effective for patients with PNH and compromised
renal function.
In the present case, the LDH level immediately prior
to treatment initiation was 1,491 U/L; it started decreas-
ing soon after eculizumab treatment initiation, returning
to normal (i.e., 234 U/L) 4 weeks later. Eculizumab pro-
tects red blood cells that lack CD55 or CD59 (also
known as “PNH-type red blood cells”) from hemolysis,
resulting in higher percentages of PNH-type red blood
cells in patients with PNH (Hillmen et al. 2010). In fact,
high percentages of PNH-type red blood cells were ob-
served in the present patient after eculizumab treatment
(54% and 47% of CD55(−) and CD59(−) cells, respectively).
This suggests that PNH-type red blood cells survived and
did not undergo hemolytic destruction.
In view of age-associated reduction in immune func-
tion and the effect of eculizumab on the suppression of
the terminal complement pathway (i.e., C5 and subse-
quent components), one concern is that treatment with
eculizumab may elevate the risk of infection in elderly
patients (Naylor et al. 2005; Czesnikiewicz-Guzik et al.
2008). Indication studies of eculizumab have been per-
formed globally including Japan. However, because of
the nature of these studies, patients aged >80 years were
rarely enrolled; the oldest patient enrolled in Japan was
aged 70 years. The major adverse events observed in that
study were headache (52%), nasopharyngitis (41%), nau-
sea (21%), and diarrhea (13%); however, no infectious
adverse events possibly associated with eculizumab treat-
ment were reported (Hillmen et al. 2010). The present
patient was diagnosed with PNH at the age of 81 years
and began receiving eculizumab treatment at the age of
84 years. This is a rare case of an elderly patient treated
with eculizumab. Moreover, the renal function of this
patient improved from CKD stage 4 to stage 3 during
eculizumab treatment.
Conclusions
Our experience with the present case indicates that even
patients aged >80 years with compromised renal func-
tion can be safely treated with eculizumab. The findings
of this case suggest that eculizumab treatment is effect-
ive and useful for improving renal function, facilitating
weaning from blood transfusion, and alleviating PNH
patients’ fear of experiencing a hemolytic attack.
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